Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

“Now with Zepbound, the revolution continues, and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more cost-effective than Wegovy ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

The company's success in this category is particularly noteworthy given the intense competition from rivals such as Novo Nordisk (NYSE:NVO)'s Ozempic and Wegovy. Eli Lilly's pipeline is another ...